Connect with us

BUSINESS

WeedMD Inc (OTCMKTS:WDDMF) Completes Harvest Of Outdoor Crop At Strathroy Facility: WeedMD Receives A License To Sell Cannabis Products

Published

on

WeedMD Inc (OTCMKTS:WDDMF) harvested cannabis outdoor crop on 27 acres at Strathroy facility, Ontario. It has to undergo processing and curing to eliminate harsh compounds and excessive moisture while retaining cannabinoids and terpenes. The company plans to harvest premium quality cannabis on 200 acres next year.

Enters commercial extraction operations

WeedMD has commenced the commercial extraction operation at the Aylmer facility. Health Canada awarded a license to allow WeedMD to manufacture and market topicals, edibles, and cannabis concentrates.

Chief Executive Officer of WeedMD, Keith Merker, said the company achieved a milestone by completing the outdoor harvest. Sitting with large amounts of cannabis, WeedMD sells the dried and other forms of cannabis in value-added formats in the coming days and quarters. It will emerge as a leader in the sale and production of cannabis extracts under economical production of the dried flower, and extraction business at the Aylmer facility.

CX Industries, a wholly-owned subsidiary of WeedMD, is capable to process 26,000 kgs of biomass every year with the recently commissioned extractor. The company will install the second Q-90 extractor rated for high throughput efficiency of CO2 in December 2019. It will install another two extractors next year. The annual extraction capacity at CX Industries would be 200,000 kgs of biomass. CX Industries and WeedMD would introduce innovative cannabis 2.0 products in January 2020 for Canadian customers.

Data-driven efficiency and transparency

WeedMD is added to the subscriber base of Strainprint Technologies. The company operates a 158-acre outdoor and greenhouse facility situated in Ontario. The annual production capacity of the greenhouse of WeedMD is over 20,000 kgs. The company also harvests an additional 20,000 kg of biomass at its Strathroy based outdoor cultivation platform that is based on 27 acres.

Senior Vice President (Marketing and Sales) of WeedMD, the main aim of working with Strainpoint is to ensure data-driven efficiency and transparency in the cannabis industry. It leverages the technology of Strainprint to bring high-quality cannabis products to the market.

WeedMD would announce Q3 results on November 28, 2019. CEO would host a conference call to discuss earnings at 10 AM on the same day.

BUSINESS

Blackbird Holdings Corp, A Subsidiary Of TILT Holdings Inc (OTCMKTS:TLLTF), Partners With Cova Software To Provide Retail Solution For Dispensaries And Cannabis Stores

Published

on

Blackbird Holdings Corp, a subsidiary of TILT Holdings Inc (OTCMKTS:TLLTF), decided to offer cannabis dispensaries and stores a retail solution to facilitate home delivery, point of sale (POS), online ordering, and customer retention by partnering with Cova Software. Following this deal, the company integrated the cannabis POS of Cova Software with its all-in-one retail platform for cannabis distribution and e-commerce.

Eliminates the need for double entries

Blackbird’s pact with Cova Software eliminates the need for double entries in in-store and online sales. It helps the cannabis stores and dispensaries to retain existing customers and attract new consumers.

Chief Executive Officer of Tilt, Mark Scatterday said Cova Software has a close relationship with its business since the beginning. The company is excited to extend that association and integrate the technologies of both Cova Software and Blackbird to offer a seamless and simple retail solution for the dispensaries and cannabis stores to manage sales and customers with ease.

The retailers of Cova POS can add dynamic online menu capabilities with the help of Blackbird. Customer records are created automatically in Cova when a customer creates an account and places an order. The order placed by the customer is automatically saved in the retail system of Cova.

Faster processing of customer orders

The integrated retail solution facilitates faster processing of orders and maintains up to date store inventory in real-time on the menus of Blackbird. It specifies product availability, product information, and pricing.

Chief Executive Officer of Cova Software, Gary Cohen said its team always strives to improve the shopping experience of customers through innovative ways and enhancements. Therefore, collaboration with Blackbird helps to create a rewarding experience for the customers across all the touchpoints and provide a simplified retail solution to the retailers. It eliminates the complexity of running a cannabis store or dispensary and ensures efficient operation.

The users of Cova will also enjoy CRM (customer relationship management) capabilities. They can develop enticing loyalty programs by integrating the rewards and loyalty capabilities of Blackbird. It helps to provide rewards to the large spenders and retain loyal customers.  Retailers can also benefit from a variety of marketing tools and indulge in sales campaigns by sending text messages.

Continue Reading

BUSINESS

State of Nevada Exempts Licensed Dispensaries And Cannabis Operators From Shut Down: 1933 Industries Inc (OTCMKTS:TGIFF) Continues To Operate As An Essential Business

Published

on

The state of Nevada has ordered shut down of all non-essential businesses. 1933 Industries Inc (OTCMKTS:TGIFF) will continue to operate as an essential business because the state of Nevada has exempted licensed dispensaries and cannabis operators from shut down.

Gives importance to safety

1933 Industries gives priority to the safety and health of its employees and partners while taking effective measures to prevent the spread of coronavirus. The company is committed to ensuring quality while maintaining solidarity with the communities in this difficult situation. All non-essential businesses are closed for the next 30-days in the state of Nevada.

1933 Industries will continue to operate its regular business amid the lockdown. It keeps all the manufacturing and cultivation operations open in Nevada to ensure the supply of premium cannabis concentrates.

Schedules second harvest for March-end

1933 Industries maintains the second harvest by the end of March 2020. It will take appropriate measures by closely monitoring the situation amid the COVID-19 pandemic. The company maintains sanitation and cleanliness in its operations while strictly following the stringent guidelines regarding safety. It is maintaining standard hygiene for all of its employees.

1933 Industries has restricted entry to visitors. It allows working of its employees in small groups to provide high-quality cannabis products and regularly monitors their health while strictly following the guidelines issued by the health authorities. The company also follows national, state, and local guidelines to protect its employees and prevent the spread of coronavirus.

1933 Industries conducts its business operations in Canada and the US. The company owns cannabis processing, extraction, cultivation, and manufacturing assets. It also holds leading cannabis brands. Portfolio of 1933 industries comprise CBD Infused Canna Hemp, AMA concentrates, AMA flower, Canna Fused, and Canna HempX. The company holds a 91% stake in the Alternative Medicine Association (AMA).

Completes new Las Vegas cultivation facility

1933 Industries has posted revenues of CAD 3.1 million in Q2 2020. It is a drop of 20% when compared to the previous quarter. The company has completed a new Las Vegas cultivation facility and commenced cultivation through its subsidiary – AMA. It also expanded its manufacturing and cultivation operations to California. The company also brought infrastructure projects in California and Nevada online while utilizing the resources.

Continue Reading

BUSINESS

Kalytera Therapeutics Inc (OTCMKTS:KALTF) Issues An Update On Acquisition Of Stero Biotechs, Ltd

Published

on

Kalytera Therapeutics Inc (OTCMKTS:KALTF) will take over Stero Biotechs, Ltd for $30 million. The company will issue its common shares worth $15 million to the shareholders of Stero. It will also issue additional common shares worth $15 million to Stero on successful completion of either phase 2a clinical trial that evaluates CBD for steroid-sparing in Chronic Urticaria and Crohn’s disease or on completing phase 2 clinical trial that evaluates CBD for steroid-sparing in any other indications. Kalytera will also issue common shares worth $5 million on commencing any phase 2a trial.

The acquisition is subject to receipt of third-party approvals

The takeover of Stero is subject to third-party and regulatory approvals. Kalytera also needs to get the approval of its shareholders and Stero’s shareholders. The share price should prevail above $0.05 CDN for this deal.

Developing CBD for co-administration with steroids

Israel based company – Stero is engaged in the development of CBD for co-administration with steroids. It helps to reduce the dosage of steroids and mitigate the safety issues in administering steroids. The company is currently conducting two phase 2a clinical trials that evaluate cannabidiol in steroid-sparing. It also has data from previous clinical trials that demonstrate the administration of steroids along with CBD considerably reduces the need for steroids. Therefore, it helps to reduce the use of steroids by up to 80%.

Extends maturity of the promissory note

Kalytera and the shareholders of its subsidiary – Talent Biotechs Ltd have agreed to extend the maturity date for the promissory note to May 15, 2020. The company expects to conclude the acquisition of Stero by May 15, 2020. Kalytera will become a leader in developing CBD pharmaceuticals with the takeover of Stero.

Chief Executive Officer and President of Kalytera, Robert Farrell, said the takeover of Stero will position the company as a leader in the development of CBD Pharmaceuticals. The US patent of Stero covers the use of cannabidiol for steroid-sparing in over 130 diseases for which steroid treatment is recommended. Therefore, the steroid-sparing program of Stero addresses large commercial opportunities. Therefore, Kalytera will have a robust CBD pharmaceutical development program, which will have great potential.

Continue Reading



Trending Stories